At All Heart Home Care, we understand that a diagnosis of Alzheimer’s or dementia doesn’t just impact the person living with the disease—it touches everyone who loves and cares for them. This guide is designed for San Diego families. Whether you’re just starting to notice signs or deep into the caregiving journey, we’re here to help you understand what’s happening and how you can best support your loved one.
What Is the Difference Between Alzheimer’s and Dementia?
Dementia is an umbrella term that describes a set of symptoms related to changes in memory, thinking, and reasoning. Alzheimer’s disease is the most common type of dementia, accounting for 60% to 80% of cases. While many people use the terms interchangeably, Alzheimer’s is a specific brain disease that progresses over time.
In Alzheimer’s, nerve cells in the brain are damaged by two abnormal structures: plaques (clusters of a protein called beta-amyloid) and tangles (twisted strands of a protein called tau). These structures disrupt communication between brain cells and eventually cause them to die.
The Numbers Behind Alzheimer’s Disease
Alzheimer’s is a growing public health crisis in the United States. According to the Alzheimer’s Association’s 2025 Facts and Figures report:
- An estimated 7.2 million Americans age 65 and older are living with Alzheimer’s dementia—about 1 in 9 people in this age group
- Almost two-thirds of Americans with Alzheimer’s are women
- Older Black Americans are about twice as likely to have Alzheimer’s or other dementias as older White Americans, and older Hispanics are about one and a half times as likely
- About 200,000 Americans under age 65 have younger-onset Alzheimer’s
- Health and long-term care costs are projected to reach $384 billion in 2025
- Nearly 12 million family members and other unpaid caregivers provide an estimated 19 billion hours of care annually
- This number could grow to 13.8 million by 2060 without medical breakthroughs
Between 2000 and 2022, deaths from Alzheimer’s disease increased by more than 142%, while deaths from stroke and heart disease decreased.
Understanding the Brain Changes in Alzheimer’s
The human brain is made up of billions of neurons that form networks responsible for everything we do. Alzheimer’s starts in the cerebrum, the largest part of the brain, which controls thought, memory, and language. Over time, neuronal death leads to brain shrinkage, impairing essential functions.
Key symptoms of this damage include:
- Memory loss
- Difficulty solving problems or making plans
- Language struggles
- Personality and behavioral changes
- Loss of physical abilities in later stages
Who Is Most at Risk?
Some risk factors can’t be changed, while others are influenced by lifestyle:
Non-modifiable risk factors:
- Age: Risk increases dramatically with age—5% of people ages 65-74, 13.2% of those 75-84, and 33.4% of those 85 and older have Alzheimer’s dementia
- Family history and genetics: The APOE-e4 gene has the strongest impact on risk of late-onset Alzheimer’s
- Ethnicity: Hispanic and Black populations are at higher risk
- Sex: Women are more likely to be affected, partially due to longer life expectancy
Modifiable risk factors:
The 2024 Lancet Commission on Dementia Prevention identified 14 modifiable risk factors that, if fully addressed, could prevent or delay nearly 45% of dementia cases worldwide. These factors vary by life stage:
• Early life (under 18): Low educational attainment
• Midlife (45-65): Hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, excessive alcohol use, hypertension, obesity
• Later life (65+): Smoking, social isolation, air pollution, untreated vision loss
The good news: Managing heart health—avoiding smoking, controlling blood pressure and cholesterol, staying active, and eating well—can significantly reduce the risk of cognitive decline.
The Stages of Alzheimer’s Disease
Alzheimer’s progresses gradually and uniquely for each person, but it generally follows three main stages. In 2024, revised diagnostic criteria were published that incorporate advances in biomarker testing to provide objective data for staging disease progression.
Early Stage (Mild):
- Subtle memory lapses
- Difficulty finding words
- Trouble remembering names or recent events
- Losing items or getting lost in familiar places
Middle Stage (Moderate):
- Increasing confusion
- Needing help with daily activities (like choosing clothes or bathing)
- Changes in sleep and mood
- Greater risk of wandering
- Personality changes, including suspicion or delusions
Late Stage (Severe):
- Loss of awareness of surroundings
- Difficulty speaking or swallowing
- Full-time assistance needed for personal care
- Increased vulnerability to infections
Advances in Diagnosis
Traditionally, diagnosing Alzheimer’s required referrals to specialists and expensive PET brain scans or lumbar punctures. Now, breakthrough blood tests are making early diagnosis more accessible:
✓ First FDA-cleared blood test (May 2025) — The Lumipulse pTau217/Beta-Amyloid 42 Ratio test measures key biomarkers through a simple blood draw, matching PET scan results more than 90% of the time.
✓ Primary care blood test (October 2025) — The Elecsys pTau181 test became the first blood-based biomarker test cleared for use in primary care settings specifically to rule out Alzheimer’s-related amyloid pathology, with a 97.9% negative predictive value.
✓ What this means for patients — Blood tests are quicker and far cheaper than brain imaging, reducing wait times and cost barriers to diagnosis. According to the 2025 Facts and Figures report, nearly 4 in 5 Americans would want to know if they had Alzheimer’s before symptoms interfered with their lives.
If you notice cognitive changes in yourself or a loved one, talk to your doctor about whether biomarker testing might be appropriate.
Treatment and Care Options
There is currently no cure for Alzheimer’s disease. However, 2023-2024 brought historic advances with the first FDA-approved treatments that address the disease’s underlying biology—not just its symptoms.
Disease-Modifying Treatments (for Early-Stage Alzheimer’s):
Two anti-amyloid monoclonal antibody therapies have received full FDA approval for people with mild cognitive impairment (MCI) or mild Alzheimer’s dementia with confirmed amyloid plaques:
• Lecanemab (Leqembi) — Received full FDA approval in July 2023. Given as an IV infusion every two weeks, it slowed cognitive decline by 27% compared to placebo in clinical trials. In January 2025, the FDA approved a less-frequent maintenance dosing option (every four weeks) and a weekly subcutaneous self-injection for at-home use following the initial treatment period.
• Donanemab (Kisunla) — Approved in July 2024. When administered monthly via IV infusion, clinical trials showed a 35% reduction in the risk of disease progression. Uniquely, treatment may be stopped once brain scans show amyloid plaques are sufficiently reduced.
Important considerations: These treatments are only approved for early-stage Alzheimer’s with biomarker-confirmed amyloid. Both carry a risk of ARIA (amyloid-related imaging abnormalities)—brain swelling or micro-bleeds detected through MRI monitoring—which is more common in people with the ApoE4 gene variant. Medicare covers medications after traditional FDA approval.
Symptom-Managing Medications:
For people at any stage of Alzheimer’s, these medications may help manage symptoms temporarily but do not stop disease progression:
- Cholinesterase inhibitors: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne)
- NMDA receptor antagonist: Memantine (Namenda)
- Combination therapy: Donepezil + Memantine (Namzaric)
Non-Drug Approaches:
Non-medication strategies are powerful tools in caring for someone with dementia:
✓ Redirect instead of correct — Meet the person where they are, rather than arguing with their reality.
✓ Create a calm, familiar environment — Reduce confusion by maintaining consistent routines and surroundings.
✓ Look for sources of discomfort — Behavioral changes may signal pain, hunger, cold, or other unmet needs.
✓ Encourage meaningful activity and rest — Music, art, gardening, and gentle exercise can improve quality of life.
Reducing Your Risk
Research continues to demonstrate that healthy lifestyle interventions can help protect cognitive function. The Alzheimer’s Association U.S. POINTER trial—a two-year multidomain lifestyle intervention—showed improved cognition in older adults at risk of cognitive decline.
Steps you can take to promote brain health:
✓ Stay physically active — Regular exercise is one of the most effective ways to reduce dementia risk.
✓ Protect your hearing and vision — Address hearing and vision loss early; the ACHIEVE trial found hearing aids reduced cognitive decline by 48% over three years in high-risk adults.
✓ Manage cardiovascular health — Control blood pressure, cholesterol, and blood sugar.
✓ Stay socially connected — Maintain relationships and engage with your community.
✓ Keep learning — Challenge your brain with new activities and continued education.
✓ Limit alcohol and don’t smoke — Both are linked to increased dementia risk.
✓ Get quality sleep — Poor sleep is associated with increased risk of cognitive decline.
Advancing Research and Hope for the Future
Alzheimer’s research has shown that brain changes begin years—even decades—before symptoms appear. Scientists are working to detect these early changes and intervene sooner. The Alzheimer’s Association invested $112.2 million in research in 2025, the largest single-year investment in its history, bringing total active investments to more than $450 million across 1,200+ projects in 56 countries.
Clinical trials offer hope and opportunities for individuals living with Alzheimer’s and their families. You can learn more or search for studies through:
- Alzheimer’s Association TrialMatch — A free matching service connecting participants with clinical trials
- ClinicalTrials.gov — The federal database of publicly and privately supported clinical studies
Support for Caregivers
Caring for someone with Alzheimer’s or dementia is one of the most challenging roles a person can take on. In 2024, nearly 12 million caregivers provided more than 19 billion hours of unpaid care valued at $413 billion. More than half of caregivers rate their emotional stress as high or very high.
New Federal Support Through the GUIDE Model:
The CMS Guiding an Improved Dementia Experience (GUIDE) Model, which began in July 2024, provides Medicare coverage for comprehensive dementia care, including:
- Care coordination and management through interdisciplinary teams
- Care Navigators to help families access services and resources
- Up to $2,500 annually for respite services per eligible patient
- Caregiver education and training programs
Resources for Caregivers:
✓ 24/7 Helpline — The Alzheimer’s Association offers round-the-clock support staffed by master’s-level clinicians at 800-272-3900, available in over 200 languages.
✓ Support Groups — Local and virtual support groups connect you with others who understand.
✓ ALZConnected — A free online community for everyone affected by dementia.
✓ The Empowered Caregiver — A new evidence-based education program designed for middle- and late-stage caregivers to build skills and manage stress.
✓ My ALZ Journey App — A free mobile app launched in 2025 that provides tailored information and local support for people newly diagnosed and their care partners.
✓ Eldercare Locator — Call 800-677-1116 or visit eldercare.acl.gov to find local services and support.
How All Heart Home Care Supports You
Our team is dedicated to walking alongside families in San Diego County with professional, heart-centered home care. We understand the nuances of Alzheimer’s disease and related dementias and tailor our support to meet each stage of the journey. From companionship and personal care to respite and advanced care needs, we are here.
Our Alzheimer’s and dementia care services include:
- Personalized care plans that adapt as needs change
- Assistance with daily activities, medication reminders, and nutrition
- Engaging activities to maintain cognitive function and quality of life
- Safety supervision and fall prevention
- Respite care to give family caregivers a much-needed break
- Compassionate companionship through every stage
You are not alone. We invite you to reach out and start a conversation. Together, we can bring peace, comfort, and dignity to every step of the Alzheimer’s journey.
Call us today at (619) 736-4677 to learn how we can support you and your loved one.
References
- Alzheimer’s Association: 2025 Alzheimer’s Disease Facts and Figures — Current prevalence, costs, and caregiver statistics
- Alzheimer’s Association: Lecanemab (Leqembi) — Information on the first disease-modifying treatment
- Alzheimer’s Association: Donanemab (Kisunla) — Information on the second disease-modifying treatment
- 2024 Lancet Commission on Dementia Prevention, Intervention, and Care — Evidence on 14 modifiable risk factors
- CMS GUIDE Model — New Medicare program for comprehensive dementia care
- FDA: First Blood Test for Alzheimer’s Disease — Information on breakthrough diagnostic advances



